April 20, 2026
4 min watch
Key takeaways:
- Eye doctors reported high satisfaction with Vyzulta as a treatment for glaucoma or ocular hypertension.
- High scores were reported for ease of use, post-drop comfort, safety and overall satisfaction.
WASHINGTON — A survey found high satisfaction rates among eye care practitioners who prescribed Vyzulta to treat open-angle glaucoma or ocular hypertension.
“There are a multitude of real-world studies looking at patients on [latanoprostene bunod] with [open-angle glaucoma] and ocular hypertension, but there is limited evidence looking at eye care practitioner, or ECP, satisfaction and utilization patterns with the product,” Jason Bacharach, MD, who presented the study at the American Society of Cataract and Refractive Surgery meeting, told Healio.
The sub-analysis of a retrospective, multicenter, cross-sectional study looked at ECP satisfaction levels with Vyzulta (latanoprostene bunod ophthalmic solution 0.024%, Bausch + Lomb) at five U.S. sites. Physicians were required to have at least 3 years of experience and to have prescribed Vyzulta to at least 10 patients.
The practices included in the analysis had an average of 538 cases of open-angle glaucoma and 87 cases of ocular hypertension per month, Bacharach said.
The number of patients treated with the solution as monotherapy or combination therapy was almost evenly split (184 and 186 patients, respectively).
When rated on a scale of 1, meaning very poor effectiveness, to 10, meaning very good effectiveness, Bacharach said that ECP satisfaction was “really high.”
“If you looked at effectiveness in people with no prior treatment, it was 9.2. If you looked at people who had failed IOP drops, it was 8, and if you looked at people who had failed SLT and MIGS, it was 8,” he told Healio.
The safety profile was also positive, scoring 9.6.
“Whether it’s ease of use, post-drop comfort or just overall satisfaction, all of those numbers were above 9,” Bacharach said.
Sources/Disclosures
Source:
Bacharach J. Utilization patterns and eye care practitioner satisfaction with latanoprostene bunod: Retrospective real-world evidence study. Presented at: American Society of Cataract and Refractive Surgery meeting; April 10-13, 2026; Washington.
Disclosures:
Bacharach reports being a consultant and investigator for Bausch + Lomb.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
<
Leave a Reply